Benzinga | Nov 30, 2021 04:43PM EST

Evogene Subsidiary Biomica Reports Results From Pre-Clinical Studies In Inflammatory Bowel Disease Program

REHOVOT, Israel, Nov. 30, 2021 /PRNewswire/ -- Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), reported today positive results from pre-clinical studies in its IBD program. In these studies, Biomica tested its optimized drug candidate BMC333, which consists of four live bacterial strains derived from Biomica's drug candidates BMC321 and BMC322, which had been previously tested as well. Treatment with these drug candidates demonstrated efficacy in several studies in reducing inflammation for the treatment of IBD.